UBS has given Novartis a 'Buy' rating and set a price target of 111 francs based on insights from a recent conference.
CFO Harry Kirsch expressed optimism about the company's growth prospects for 2025, coinciding with the expiration of the Entresto patent.
Analyst Matthew Weston highlighted this confidence in a report released on Thursday. The endorsement from UBS suggests that Novartis is well-positioned to navigate challenges, particularly patent expirations. This information may be relevant to investors assessing growth potential in the pharmaceutical sector.